Single-dose pyridostigmine during invasive exercise testing
Joseph P et al. · 2022 · Chest
Indexed 2026-11-12.
Reported findings and study design
Reported findings
One oral 60 mg dose or placebo after the first invasive cardiopulmonary exercise test. A second test took place 50 minutes later.
Dose, route and schedule
One oral 60 mg dose or placebo after the first invasive cardiopulmonary exercise test. A second test took place 50 minutes later.
Protocol source ↗ · Original article abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Change in peak oxygen uptake | +13.3 ± 13.4 mL/min with pyridostigmine versus −40.2 ± 21.3 with placebo (p<0.05). | |
| Right atrial pressure, peak minus rest | Change +1.0 ± 0.5 versus −0.6 ± 0.5 mm Hg (p<0.05). |
The study measured immediate physiology in a selected group. It did not test sustained function or delayed symptom recovery.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The study measured immediate physiology in a selected group. It did not test sustained function or delayed symptom recovery.
Related publications may cover the same research program or participants.
Source access
One oral 60 mg dose or placebo after the first invasive cardiopulmonary exercise test. A second test took place 50 minutes later.
Source reviewed 2026-11-12.
Citation and original source
Original source: Joseph P et al.. Single-dose pyridostigmine during invasive exercise testing Chest 2022.
Molekul research summary: https://molekul.io/research/pyridostigmine-icpet-2022. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry